N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells  by Abdel-Wahab, Yasser H.A. et al.
N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic
action on clonal pancreatic B-cells
Yasser H.A. Abdel-Wahab a;*, Finbarr P.M. O’Harte a, Mark H. Mooney a,
J. Michael Conlon b, Peter R. Flatt a
a School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK
b Regulatory Peptide Center, Department of Biomedical Science, Creighton University Medical School, Omaha, NE, USA
Received 1 April 1999; received in revised form 22 June 1999; accepted 22 July 1999
Abstract
Monoglycated cholecystokinin octapeptide (Asp1-glucitol CCK-8) was prepared under hyperglycaemic reducing
conditions and purified by reverse phase-high performance liquid chromatography. Electrospray ionisation mass
spectrometry and automated Edman degradation demonstrated that CCK-8 was glycated specifically at the amino-terminal
Asp1 residue. Effects of Asp1-glucitol CCK-8 and CCK-8 on insulin secretion were examined using glucose-responsive clonal
BRIN-BD11 cells. In acute (20 min) incubations, 10310 mol/l CCK-8 enhanced insulin release by 1.2^1.5-fold at 5.6^11.1
mmol/l glucose. The stimulatory effect induced by 10310 mol/l CCK-8 was abolished following glycation. At 5.6 mmol/l
glucose, CCK-8 at concentrations ranging from 10311 to 1037 mol/l induced a significant 1.6^1.9-fold increase in insulin
secretion. Insulin output in the presence of Asp1-glucitol CCK-8 over the concentration range 10311^1037 mol/l was
decreased by 21^35% compared with CCK-8, and its insulinotropic action was effectively abolished. Asp1-glucitol CCK-8 at
1038 mol/l also completely blocked the stimulatory effects of 10311^1038 mol/l CCK-8. These data indicate that structural
modification by glycation at the amino-terminal Asp1 residue effectively abolishes and/or antagonises the insulinotropic
activity of CCK-8. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cholecystokinins (CCKs) constitute a family of
hormonal and neuronal peptides that exhibit pleio-
tropic e¡ects in the brain, gut and pancreas [1,2].
Molecular forms of CCK ranging from 4 to 58 ami-
no acids have been identi¢ed and the dominant
forms found in the circulation after feeding are
CCK-8, CCK-22, CCK-33, CCK-39 and CCK-58
[3]. The C-terminal sulphated octapeptide CCK-8 is
well conserved across species and is the smallest form
to retain a full range of biological activities [2,4].
CCK is secreted by endocrine cells in the duode-
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num and proximal jejunum of the small intestine in
response to absorption of digested food components
such as amino acids [5]. The feeding-induced release
of CCK is indicative of an important role as a phys-
iological regulator of digestion and post-prandial nu-
trient homeostasis. Indeed, many studies have dem-
onstrated that CCK is an important satiety factor,
regulator of intestinal motility and key stimulus for
gall bladder contraction [1,2]. It also stimulates the
secretion of pancreatic enzymes and insulin from the
B-cells of the islets of Langerhans [1,2]. The action
on the pancreatic B-cells [6,7] is notable as CCK is
one of the strongest stimulators of islet phospho-
lipase C, leading to activation of signal transduction
pathways involving inositol trisphosphate, diacyl-
glycerol, protein kinase C and phospholipase A2
[8,9]. Thus, CCK together with conjoint parasym-
pathetic nerve activation and release of enteroinsular
hormones, such as gastric inhibitory polypeptide
(GIP) and glucagon-like peptide 1 (tGLP-1), are
considered key determinants of the early ‘cephalic’
insulin response to meal ingestion [10,11].
Recent studies have indicated that structural mod-
i¢cations of peptide hormones by glycation can alter
their biological potencies [12^16]. Whereas N-termi-
nal glycation of insulin and tGLP-1 compromises
their actions on target cells [12^14], glycation of
GIP is associated with a considerable augmentation
of insulin releasing activity both in vitro and in vivo
[16,17]. We have recently demonstrated that glyca-
tion of CCK-8 markedly enhances its satiating activ-
ity when administered to mice prior to refeeding [15].
This action appears to be due in part to the fact that
N-terminal glycation a¡ords signi¢cant protection of
the peptide against proteolytic degradation and inac-
tivation by serum peptidases [15].
Since CCK-8 is an e¡ective inhibitor of feeding in
humans [18,19], these observations raise the possibil-
ity that glycated CCK-8 administration may have a
potential therapeutic use in the management of obe-
sity [15]. Furthermore, there is evidence that CCK-8
administration may be of bene¢t in patients with
NIDDM [9,20]. The purpose of the present study
was to examine the e¡ects of long-acting Asp1-gluci-
tol CCK-8 on insulin secretion from clonal pancre-
atic B-cells to assess whether glycation modi¢es the
insulinotropic activity of the peptide.
2. Materials and methods
2.1. Materials
Cholecystokinin sulphated octapeptide (CCK-8;
Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-amide)
was purchased from the American Peptide Company
(Sunnyvale, CA, USA). High performance liquid
chromatography (HPLC) grade acetonitrile was ob-
tained from Rathburn (Walkersburn, UK). Sequenc-
ing grade tri£uoroacetic acid (TFA) was obtained
from Aldrich (Poole, UK). All water was puri¢ed
using a Milli-Q Water Puri¢cation System (Millipore
Corporation, Millford, MA, USA). RPMI 1640 tis-
sue culture medium, foetal calf serum, penicillin and
streptomycin were purchased from Gibco Life Tech-
nologies, Paisley, Strathclyde, UK. Na125I (100 mCi/
ml) for iodination of insulin was from Amersham
International plc, Aylesbury, UK. Rat insulin stand-
ard was obtained from Novo Industria, Copenhagen,
Denmark. All other chemicals were purchased from
Sigma, Poole, UK.
2.2. Preparation of glycated CCK-8
Glycated CCK-8 was prepared and puri¢ed by
HPLC as described previously [15]. In brief, CCK-8
was incubated with glucose under reducing condi-
tions in 10 mmol/l sodium phosphate bu¡er pH 7.4
for 24 h. Control CCK-8 (non-glycated) was pre-
pared in an identical manner except for the exclusion
of glucose from the incubation mixture. The reaction
was stopped by addition of 0.5 mol/l acetic acid and
the sample mixture applied to a 250U4.6 mm Vydac
C-18 analytical column (The Separations Group,
Hesperia, USA) and gradient elution conditions
were established using aqueous/TFA and acetoni-
trile/TFA solvents, as described previously [15].
Pooled glycated or control CCK-8 fractions were
concentrated under vacuum (AES 1000 Savant, Life
Sciences International, Runcorn, UK). They were
then puri¢ed to homogeneity on a 150U4.6 mm Su-
pelcosil C-8 column (Supelco, Poole, UK). Control
and glycated CCK-8 samples were quanti¢ed using
the Supelco C-8 column by comparing the peak areas
with a standard curve constructed from known con-
centrations of CCK-8.
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2.3. Structural characterisation
Glycated CCK-8 and control CCK-8 were dis-
solved (approximately 400 pM) in 100 Wl of water
and analysed by electrospray ionisation mass spec-
trometry (ESI-MS). Samples were applied to the
LC/MS equipped with a microbore C-18 HPLC col-
umn (150U2.0 mm, Phenomenex UK, Maccles¢eld,
UK). Samples (30 Wl direct loop injection) were ap-
plied at a £ow rate of 0.2 ml/min, under isocratic
conditions 35% acetonitrile/water. Mass spectra
were recorded on a Finnigan LCQ benchtop mass
spectrometer (Finnigan MAT, Hemel Hempstead,
UK) and spectra were obtained from the quadrupole
ion trap mass analyser. Spectra were collected using
full ion scan mode over the mass-to-charge (m/z)
range 150^2000. The primary structure of glycated
CCK-8 was determined by automated Edman degra-
dation, using an Applied Biosystems model 471A
sequenator modi¢ed for on-line detection of phenyl-
thiohydantoin (PTH) amino acids under gradient
elution conditions [15].
2.4. Culture of insulin-secreting cells
BRIN-BD11 cells were cultured in RPMI 1640
tissue culture medium containing 10% (v/v) foetal
calf serum, 1% (v/v) antibiotics (100 U/ml penicillin,
0.1 mg/ml streptomycin) and 11.1 mmol/l glucose.
The production and characterisation of BRIN-
BD11 cells are described elsewhere [21]. Cells were
maintained in sterile tissue culture £asks (Corning,
Glass Works, UK) at 37‡C in an atmosphere of
5% CO2 and 95% air using a LEEC incubator
(Laboratory Technical Engineering, Nottingham,
UK).
Fig. 1. (A) Reverse phase (RP)-HPLC pro¢le for the separation of glycated and non-glycated CCK-8 on a Vydac C-18 column.
(B) Molecular mass determination of glycated CCK-8. Glycated CCK-8 was seen to elute at 18.84 min and to be followed at
19.51 min by CCK-8. After completion of the HPLC puri¢cation, the molecular masses of CCK-8 (Mr 1142.3) and glycated CCK-8
(Mr 1305.3) were determined by ESI-MS.
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2.5. Acute tests for insulin secretion
Insulin release was determined using monolayers
of BRIN-BD11 cells. The cells were harvested with
the aid of trypsin/EDTA (Gibco Life Technologies,
Paisley, Strathclyde, UK), seeded into 24-well plates
(Nunc, Roskilde, Denmark) at a density of 2.5U105
cells per well and allowed to attach during overnight
culture. Acute studies of insulin release were pre-
ceded by 40 min pre-incubation at 37‡C in 1.0 ml
Krebs Ringer bicarbonate bu¡er (115 mmol/l NaCl,
4.7 mmol/l KCl, 1.28 mmol/l CaCl2, 1.2 mmol/l
KH2PO4, 1.2 mmol/l MgSO4, 10 mmol/l NaHCO3
and 0.1% (w/v) bovine serum albumin, pH 7.4) sup-
plemented with 1.1 mmol/l glucose. Test incubations
were performed at 37‡C using the same bu¡er sup-
plemented with varying glucose concentrations,
structurally modi¢ed CCK-8 or control CCK-8 as
indicated in the ¢gures. After 20 min incubation,
the bu¡er was removed from each well and aliquots
were stored at 320‡C for subsequent measurement
of insulin by radioimmunoassay [22].
2.6. Statistical analysis
Groups of data are presented as means þ S.E.M.
Statistical evaluation was performed using Student’s
unpaired t-test. Di¡erences were considered to be
signi¢cant if P6 0.05.
3. Results
3.1. HPLC separation and structural characterisation
of glycated and non-glycated CCK-8
Glycated CCK-8 and non-glycated CCK-8 were
clearly resolved by separation on a Vydac C-18
HPLC column with retention times of 18.84 min
and 19.51 min, respectively (Fig. 1A). The molecular
masses of glycated CCK-8 and control CCK-8 deter-
mined by ESI-MS were Mr 1305.3 and Mr 1142.3,
respectively. The di¡erence between the observed
molecular masses (163.0 Da) indicated that the
glycated peptide contained a single glucitol adduct
(theoretical mass 164 Da) corresponding to mono-
glycated CCK-8 (Fig. 1B). Automated Edman
degradation of monoglycated CCK-8 gave a yield
of PTH-amino acids (in pmol) in consecutive cycles
of: Asp (6), Tyr (283), Met (348), Gly (205), Tyr
(155), Met (286), Asp (189) and Phe (65). The yield
in the ¢rst cycle shows that Asp1 was almost com-
pletely absent, indicating that the amino terminus
was blocked. This evidence combined with the data
from mass spectrometry clearly indicates that CCK-8
is glycated at the amino terminal Asp1 residue.
3.2. E¡ects of Asp1-glucitol CCK-8 and CCK-8 on
insulin secretion
As indicated in Fig. 2, 5.6^16.7 mmol/l glucose
induced a signi¢cant 3.0^4.5-fold stepwise stimula-
tion of insulin secretion. Addition of 10310 mol/l
CCK-8 signi¢cantly enhanced insulin release by
1.2^1.5-fold at 5.6^11.1 mmol/l glucose. In contrast,
10310 mol/l Asp1-glucitol CCK-8 failed to stimulate
insulin release at all glucose concentrations tested.
Compared with CCK-8, insulin secretion at 5.6^
11.1 mmol/l glucose was 21% less in the presence
of the structurally modi¢ed peptide.
Concentration-dependent studies of CCK-8
(10314^1037 mol/l) conducted at 5.6 mmol/l glucose
revealed a 1.6^1.9-fold stimulation of insulin release
Fig. 2. The e¡ects of glucose and 10310 mol/l Asp1-glucitol
CCK-8 or CCK-8 on insulin secretion. After 40 min of preincu-
bation, the e¡ects of glucose in the absence and presence of
10310 mol/l peptide were tested during 20 min incubation. Val-
ues are means þ S.E.M. for eight separate observations.
***P6 0.001 compared with 0 mmol/l glucose alone (control).
OP6 0.05, OOOP6 0.001 compared to the same glucose con-
centration without peptide, P6 0.05, P6 0.001 compared
with CCK-8 at the same glucose concentration.
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at concentrations of 10311 mol/l and above (Fig. 3).
Glycation of CCK-8 abolished the stimulatory e¡ects
of the peptide when tested over the range 10311^1037
mol/l compared with 5.6 mmol/l glucose alone.
To evaluate possible interactions between Asp1-
glucitol CCK-8 and CCK-8, peptide combinations
were tested. As shown in Fig. 4, 1038 mol/l Asp1-
glucitol CCK-8 decreased by 7^24% insulin release
induced by 10311^1037 mol/l CCK-8. The stimula-
tory e¡ects of the peptide at all but the highest con-
centration (1037 mol/l) were abolished by Asp1-glu-
citol CCK-8.
4. Discussion
CCK-8 was glycated in vitro under hyperglycaemic
reducing conditions which permitted puri¢cation of
the stable Asp1-glucitol adduct of CCK-8. This novel
peptide has recently been shown to be a potent in-
hibitor of food intake [15], raising interesting ques-
tions concerning its possible therapeutic, physiologi-
cal and pathophysiological roles. Further studies are
required to clarify these issues and to determine
whether Asp1-glucitol CCK-8 occurs in vivo. How-
ever, it is notable that insulin and tGLP-1 which can
be glycated in vitro also exist naturally in pancreas
or intestine [14,23^25].
The current study examined the e¡ects of CCK-8
and Asp1-glucitol CCK-8 on insulin secretion using
the clonal pancreatic BRIN-BD11 cell line. This rel-
atively new cell line, derived from electrofusion of rat
pancreatic B-cells with immortal RINm5F cells, is
glucose sensitive and exhibits good responsiveness
to a wide range of peptides and neurotransmitter
substances [14,16,21,26,27]. Consistent with this
view, CCK-8 exhibited insulinotropic e¡ects on
BRIN-BD11 cells at peptide concentrations from
10311 to 1037 mol/l. As noted elsewhere, this action
was glucose-dependent [6,7,28], being demonstrable
with the clonal B-cells only at moderate glucose con-
centrations of 5.6 and 11.1 mmol/l.
The mechanism of CCK-8 stimulated insulin re-
lease is complementary to the main pathways in-
duced by glucose and it appears to involve binding
to a speci¢c subtype of CCKA receptors on the B-cell
[6,28,29]. This triggers a complex series of events in-
volving stimulation of phospholipase C and the pro-
duction of inositol trisphosphate and diacylglycerol
[8,30^32]. The former augments intracellular Ca2 by
Fig. 4. The e¡ects of 1038 mol/l Asp1-glucitol CCK-8 on insulin
secretion induced by 10311^1037 mol/l CCK-8 at 5.6 mmol/l
glucose. After 40 min pre-incubation, the e¡ects of 10311^1037
mol/l CCK-8 were tested in the presence and absence of 1038
mol/l Asp1-glucitol CCK-8 during a 20 min incubation period.
Values are means þ S.E.M. for eight separate observations.
*P6 0.05, **P6 0.01, ***P6 0.001 compared with 5.6 mmol/l
glucose alone (control). OP6 0.05, OOP6 0.01 compared with
the same CCK-8 concentration without added Asp1-glucitol
CCK-8.
Fig. 3. The e¡ects of various concentrations of Asp1-glucitol
CCK-8 or CCK-8 on insulin release at 5.6 mmol/l glucose.
After 40 min preincubation, the e¡ects of various concentra-
tions of peptide (10314^1037 mol/l) were tested during a 20 min
incubation period. Values are means þ S.E.M. for eight separate
observations. **P6 0.01, ***P6 0.001 compared with 5.6
mmol/l glucose alone (control). OP6 0.05, OOP6 0.01 com-
pared with CCK-8 at the same peptide concentration.
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a¡ecting endoplasmic reticulum calcium stores
whereas diacylglycerol activation of protein kinase
C induces protein phosphorylation to enhance the
Ca2 sensitivity of the insulin exocytotic machinery
[33]. Recent studies also indicate that CCK-8 pro-
motes the generation of arachidonic acid through
activation of both Ca2-dependent and Ca2-inde-
pendent phospholipase A2 [9]. The glucose sensitivity
of the CCK-8 e¡ect may re£ect dependence on glu-
cose metabolism to elevate intracellular Ca2 or in-
£uence other key elements of the phospholipase C
pathway [30]. Maximal e¡ects of CCK-8 on insulin
release are known to occur at concentrations around
10 mmol/l glucose [6,7,28]. However, the mechanism
underlying the relative ine¡ectiveness of CCK-8 at
16.7 mmol/l glucose is unclear. Interestingly, such
an e¡ect has been noted recently for tGLP-1
[14,34,35], indicating that both peptides are particu-
larly well equipped to in£uence insulin secretion over
a restricted physiological glucose concentration
range.
A key ¢nding of the present paper is that glycation
of CCK-8 at the K-amino Asp1 site severely compro-
mised the insulinotropic action of the peptide. Activ-
ity was decreased by up to 35% compared with
CCK-8 and the Asp1-glucitol CCK-8 failed to stim-
ulate insulin release over the entire concentration
range of 10311^1037 mol/l. This decrease of biolog-
ical activity extends previous observations that glyc-
ation of peptides can signi¢cantly alter their biolog-
ical potencies [12^16]. However, the decreased
insulinotropic activity of Asp1-glucitol CCK-8 con-
trasts sharply with our recent observation that glyc-
ation of CCK-8 considerably augments its potency
as a peripherally acting satiety agent [15]. Thus,
although part of the in vivo e¡ect may be due to
increased resistance of Asp1-glucitol CCK-8 to serum
aminopeptidase degradation [15], receptor-mediated
e¡ects on the central nervous system are clearly in-
tact. It appears therefore that glycation of CCK-8
speci¢cally impairs the function of the CCKA recep-
tor subtype involved in insulin secretion [28] without
greatly a¡ecting receptor binding and signal trans-
duction pathways involved in feeding at target cells
endowed with other CCKA receptor subtypes or
CCKB receptors [28,36,37].
Further studies including observations using hu-
man islets, are clearly warranted to elucidate the
mechanism underlying the glycation-induced de-
crease of insulinotropic potency. CCK-7 is consider-
ably less potent than CCK-8 in stimulating insulin
release [38], suggesting that N-terminal modi¢cation
of the parent peptide may interfere with receptor
binding. In fact, the present demonstration that
Asp1-glucitol CCK-8 was able to e¡ectively abolish
the insulin stimulatory action of 10311^1037 mol/l
CCK-8 suggests that the modi¢ed peptide may act
as an antagonist at the CCKA receptor subtype on
pancreatic B-cells. This possibility contrasts with the
enhanced insulinotropic activity of Tyr1-glucitol GIP
[16], but it strongly parallels the antagonistic proper-
ties of some N-terminally modi¢ed analogues of
GLP-1(7^36)amide at the islet tGLP-1 receptor
[14,39^43].
In summary, this paper demonstrates that glyca-
tion of CCK-8 at the K-amino group of Asp1 abol-
ishes/antagonises the insulinotropic action of the
peptide. Thus unlike long-acting analogues of
tGLP-1 and GIP which are under consideration for
NIDDM therapy [17,42], the aminopeptidase resist-
ant Asp1-glucitol adduct of CCK-8 o¡ers no promise
as a novel long-acting insulin-releasing drug. How-
ever, the observation that glycation of CCK-8 mark-
edly enhances its peripheral satiety e¡ect without in-
£uencing insulin secretion, and thereby avoiding any
threat of mounting insulin resistance or hypoglycae-
mia, favours a therapeutic potential of this structur-
ally modi¢ed form of CCK-8 as a novel anti-obesity
agent [15].
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